Norgine Completes Acquisition of Theravia

Norgine, a specialized pharmaceutical and healthcare consumer company, has announced the completion of its acquisition of Theravia, an international pharmaceutical firm focused on treatments for patients with rare and debilitating diseases. This acquisition marks a significant milestone in Norgine's strategy of addressing unmet medical needs with life-changing medications. With an annual revenue exceeding 550 million euros and over a century of experience, Norgine plans to integrate Theravia into its operations, aligning systems and teams to effectively expand their product reach in Europe, Australia, and New Zealand. The acquisition solidifies Theravia as a wholly-owned subsidiary of Norgine, enhancing Norgine's capabilities in the rare disease sector and supporting its ongoing growth strategy. CEO Janneke van der Kamp emphasized the critical role of this acquisition in Norgine's objectives to expand product offerings to high-need regions, ensuring transformative medicines reach a broader patient base.